Prostate Cancer Treatment Options by Stage: Comprehensive Overview

Prostate cancer management is highly individualized based on stage, grade (Gleason/Grade Group), PSA, patient age/comorbidities, preferences, and life expectancy.

Risk Stratification (Localized Disease)

• Very low / Low risk: Grade Group 1 (Gleason 3+3), PSA < 10, cT1c–T2a. → Active Surveillance (AS) preferred.
• Intermediate risk (Favorable/Unfavorable): Grade Group 2–3, PSA 10–20, cT2b–T2c. → AS (favorable) or definitive treatment.
• High / Very high risk: Grade Group 4–5, PSA > 20, cT3a. → Definitive treatment +/− ADT.

Localized (cT1–T2, N0, M0) – Curative Intent

• Active Surveillance: Serial PSA, DRE, MRI, repeat biopsy. Avoids overtreatment. 50–70% remain untreated at 10–15 yrs.
• Radical Prostatectomy (RP): Open, laparoscopic, robotic (RARP). Removes prostate + seminal vesicles ± lymph nodes. Best long-term cancer control data. Risks: incontinence (5–20% long-term), erectile dysfunction (nerve-sparing helps).
• Radiation Therapy (RT):
  • External Beam RT (EBRT): IMRT/VMAT, SBRT (5 fractions), proton therapy. 7–9 weeks (conventional) or 5 fx (SBRT).
  • Brachytherapy (LDR/HDR): Radioactive seeds/temporary catheters. Excellent for low-intermediate.
• Focal Therapy (Emerging): HIFU, cryotherapy, irreversible electroporation, PDT, laser. Targets index lesion only. Preserves function. Not standard of care – select patients, registry data.

Locally Advanced (cT3–T4, N0, M0)

• RT + ADT (18–36 months) = standard.
• RP + adjuvant/salvage RT ± ADT (selected).
• Multimodal trials (e.g., STAMPEDE, PEACE-1) show survival benefit for early ADT + docetaxel/abiraterone in high-risk.

Metastatic (M1) – Systemic Therapy

• ADT (GnRH agonist/antagonist) – Backbone. Medical castration (T < 50 ng/dL).
• Androgen pathway inhibitors: Abiraterone, enzalutamide, apalutamide, darolutamide (↑ survival in mHSPC).
• Chemotherapy: Docetaxel (mHSPC, mCRPC). Cabazitaxel (post-docetaxel).
• Radiopharmaceuticals: ¹⁷⁷Lu-PSMA-617 (VISION trial, mCRPC), ²²³Ra (bone mets).
• PARP inhibitors: Olaparib, rucaparib (HRR mutations, mCRPC).
• Immunotherapy: Sipuleucel-T (mCRPC, asymptomatic/minimally symptomatic). Pembrolizumab (MSI-H/dMMR).

Shared Decision-Making

Use decision aids (e.g., NCCN, PCRI). Discuss cure probability, functional outcomes (urinary, sexual, bowel), timeline, cost, values. Multidisciplinary tumor board for complex cases.